Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Checkerspot is a biology driven, molecule licensing company designing fats and oils through precision fermentation.
Melonfrost is a biotechnology company based in Brooklyn, New York.
Spora Health is a primary care provider designed for people of color.
FYTO is a technology company that develops systems for farmers to grow crops using fewer resources.
Evernow develops an online teleconsultation platform that focuses on women's long-term health.
Redesign Science is a computational chemistry company setting a new standard for early-stage, small molecule drug discovery.
Industrial-scale genome sequencing
Legalist is an institutional alternative asset management firm. The firm uses data-driven technology to invest in credit assets at scale.
Manufacturing execution system rebuilt around a modern technology stack.
Alloy.ai is an inventory management platform that tracks sales, promotions, and cut-out-of-stocks and manages inventory levels.
Enzyme is building software to help life sciences companies with FDA approval and regulatory compliance.
TL Biolabs offers economical genomic tests for beef and dairy cattle, with free software to deliver actionable results.
Refactor has invested in 60 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Refactor's top investment sectors include Biotechnology, Software, Health Care, Life Science, Manufacturing. The firm invests across 32 different industry categories.
Among tracked funding rounds, Legalist received $100.0M in a Series Unknown round. Refactor's total known invested capital is $1.2B.
Refactor's average investment size is $22.4M across its portfolio of 60 companies.
Recent Refactor portfolio additions include Checkerspot, Melonfrost, Spora Health, FYTO, Evernow. These companies were founded in 2020 or later.